Vaxil Long Term Debt To Capitalization from 2010 to 2024
| VXL Stock | CAD 0.01 0.00 0.00% |
Long Term Debt To Capitalization | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Vaxil Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxil Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 114, Selling And Marketing Expenses of 17.1 or Other Operating Expenses of 241, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.9. Vaxil financial statements analysis is a perfect complement when working with Vaxil Bio Valuation or Volatility modules.
Vaxil | Long Term Debt To Capitalization |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.